Connect
← Return to Prolia discontinuation
Discussion
Comment receiving replies
My local clinic also told me that they are switching to biosimilar Jubbonti and not offering Prolia anymore. Since two years ago an Endocrinologist at Mayo told me to stay on Prolia up to 12 years because of its anti-bone tumor properties and I have lung cancer, I have no intention of switching drugs to please my local clinic. I called Medicare and they continue to cover Prolia so there is no benefit for me. They obviously have a financial benefit. It is unethical!
Obviously these new biosimilars do not have the data history of Prolia and I am not going to experiment given my situation. I found a local Endocrinologist who has researched Osteoporosis in women with breast cancer, so I made an appointment with her. I thankfully have original Medicare and can go wherever they take Medicare.
Replies to "My local clinic also told me that they are switching to biosimilar Jubbonti and not offering..."
I have a friend who was recently notified that Jubbonti would be substituted for Prolia. She is requesting that I inquire of those on this forum who your healthcare insurers are. Thank you !
Connect
Thank you for responding. Since my last post I have experienced skin eruptions around my mouth and bone pain, none of which I had the past 5 years on Prolia. I did more research and found that the half life of denosumab is 26 days, so, it will take almost a month before even 50% of this drug is cleared from my system. I also read that it peaks in 10 days. My last post was before the 10 day mark and that may have factored into the additional side effects I am experiencing. I wonder if Sutter is getting the drug at a phenomenally reduced price as they are using their patients for post marketing statistics, the stage 4 trial of a new drug. Once again, thank you for your response. I am a breast cancer survivor and appreciate the new fact I learned that Prolia has anti-bone tumor properties. That kind of makes me reconsider trying Prolia, again, in 6 months, rather than switching to fosamax.